• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell-free production of trimeric influenza hemagglutinin head domain proteins as vaccine antigens

tetano

Editor, Senior Moderator
Biotechnol Bioeng. 2012 Jun 21. doi: 10.1002/bit.24581. [Epub ahead of print]
Cell-free production of trimeric influenza hemagglutinin head domain proteins as vaccine antigens.
Welsh JP, Lu Y, He XS, Greenberg HB, Swartz JR.
Source

Department of Chemical Engineering, Stanford University, Stanford, CA 94305.
Abstract

In order to effectively combat pandemic influenza threats, there is a need for more rapid and robust vaccine production methods. In this paper, we demonstrate E. coli-based cell-free protein synthesis (CFPS) as a method to rapidly produce domains from the protein hemagglutinin (HA), which is present on the surface of the influenza virus. The portion of the HA coding sequence for the 'head' domain from the 2009 pandemic H1N1 strain was first optimized for E. coli expression. The protein domain was then produced in CFPS reactions and purified in soluble form first as a monomer and then as a trimer by a C-terminal addition of the T4 bacteriophage foldon domain. Production of soluble trimeric HA head domain was enhanced by introducing stabilizing amino acid mutations to the construct in order to avoid aggregation. Trimerization was verified using size exclusion HPLC, and the stabilized HA head domain trimer was more effectively recognized by antibodies from pandemic H1N1 influenza vaccine recipients than was the monomer and also bound to sialic acids more strongly, indicating that the trimers are correctly formed and could be potentially effective as vaccines. Biotechnol. Bioeng. ? 2012 Wiley Periodicals, Inc.

Copyright ? 2012 Wiley Periodicals, Inc.

PMID:
22729608
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/22729608
 
Back
Top Bottom